# Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

> **NCT02221180** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 2 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]
- **DRUG:** Canagliflozin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02221180
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2014-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02221180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02221180, "Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02221180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*